World's Best Scientists 2026 revealed!
Tanios Bekaii-Saab

Tanios Bekaii-Saab

D-Index & Metrics

Biology and Biochemistry

D-Index
74
Citations
22367
World Ranking
5537
National Ranking
2631

Overview

Tanios Bekaii-Saab is affiliated with the Mayo Clinic in the United States and has a focused research portfolio in medicine, particularly in oncology. Their work encompasses various subfields including oncology, pulmonary and respiratory medicine, surgery, cancer research, and pathology and forensic medicine.

The scientist's research covers a range of main topics, such as:

  • Colorectal Cancer Treatments and Studies
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Gastric Cancer Management and Outcomes
  • Cancer Immunotherapy and Biomarkers
  • Genetic factors in colorectal cancer

Some of their most cited recent papers include:

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, 2020, The Lancet
  • Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C, 2022, New England Journal of Medicine
  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study, 2021, The Lancet. Gastroenterology & Hepatology
  • NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial, 2023, The Lancet
  • Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium, 2021, Annals of Oncology

The scientist frequently collaborates with a group of coauthors, including:

  • Daniel H. Ahn
  • Mohamad Bassam Sonbol
  • Mitesh J. Borad
  • John H. Strickler
  • Pedro Luiz Serrano Usón

Their work is published predominantly in journals such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • ONCOLOGY
  • The Oncologist
  • European Journal of Cancer

Best Publications

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Andrea Wang-Gillam;Chung-Pin Li;György Bodoky;Andrew Dean

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101.

    Matthew H.G. Katz;Qian Shi;Syed A. Ahmad;Joseph M. Herman

  • IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

    Thomas A Mace;Reena Shakya;Jason R Pitarresi;Benjamin Swanson

  • Pain, depression, and fatigue: loneliness as a longitudinal risk factor.

    Lisa M. Jaremka;Rebecca R. Andridge;Christopher P. Fagundes;Catherine M. Alfano

  • Pancreatic Cancer-Associated Stellate Cells Promote Differentiation of Myeloid-Derived Suppressor Cells in a STAT3-Dependent Manner

    Thomas A Mace;Zeenath Ameen;Amy Collins;Sylwia E. Wojcik

  • Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.

    Rachna T. Shroff;Erin B. Kennedy;Melinda Bachini;Tanios Bekaii-Saab

  • Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.

    Van K. Morris;Mohamed E. Salem;Halla Nimeiri;Syma Iqbal

  • Biliary cancer: Utility of next-generation sequencing for clinical management.

    Milind Javle;Tanios Bekaii-Saab;Apurva Jain;Ying Wang

  • Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

    Rachna T. Shroff;Milind M. Javle;Lianchun Xiao;Ahmed O. Kaseb

  • Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers

    Tanios Bekaii-Saab;Mitch A. Phelps;Xiaobai Li;Motoyasu Saji

  • Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.

    Milind Javle;Sameek Roychowdhury;Robin Kate Kelley;Saeed Sadeghi

  • Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

    P. Grivas;A. R. Khaki;A. R. Khaki;T. M. Wise-Draper;B. French

  • Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines

    Al B. Benson;Alan P. Venook;Tanios Bekaii-Saab;Emily Chan

  • Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas

    Marlo Blazer;Christina Wu;Richard M. Goldberg;Gary Phillips

  • Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis

    Quisette P. Janssen;Stefan Buettner;Mustafa Suker;Berend R. Beumer

  • Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

    Tanios S. Bekaii-Saab;Fang Shu Ou;Daniel H. Ahn;Patrick M. Boland

  • Colon Cancer, Version 3.2014

    Al B. Benson;Alan P. Venook;Tanios Bekaii-Saab;Emily Chan

  • Gastric cancer: Clinical practice guidelines in oncology™

    Jaffer A. Ajani;James S. Barthel;Tanios Bekaii-Saab;David J. Bentrem

Frequent Co-Authors

Richard M. Goldberg
Richard M. Goldberg West Virginia University
Axel Grothey
Axel Grothey University of Tennessee at Knoxville
Ching-Shih Chen
Ching-Shih Chen The Ohio State University
Alan P. Venook
Alan P. Venook University of California, San Francisco
Michael R. Grever
Michael R. Grever The Ohio State University
William E. Carson
William E. Carson The Ohio State University
Gregory A. Otterson
Gregory A. Otterson The Ohio State University
Robin Kate Kelley
Robin Kate Kelley University of California, San Francisco
Denis C. Guttridge
Denis C. Guttridge Medical University of South Carolina

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Biology or Biochemistry opens the door to a wide range of related online degrees. Many students pursue advanced healthcare leadership roles, and you can do so flexibly with dnp program no clinical requirements if you’re interested in nursing leadership without extensive clinical hours.

Those drawn to health services administration can consider doctoral programs for healthcare administration. These programs emphasize strategic management skills for healthcare settings, making them a top choice for future hospital and clinic leaders.

Pharmacy is a common next step for Biochemistry graduates, and flexible online pharm d programs let you work towards becoming a licensed pharmacist from anywhere, often while fulfilling professional obligations.

If you’re interested in human physiology, wellness, or sports science, consider an online exercise science degree. Careers in this field range from athletic training to rehabilitation and fitness management. Each of these online degrees can complement a background in Biology or Biochemistry and help expand your career options in the healthcare and science sectors.

Best Scientists Citing Tanios Bekaii-Saab

Trending Scientists